Abstr Act: Cancer is a complex disease that arises from the alterations in the composition and regulation of several genes leading to the disturbances in signaling pathways, resulting in the dysregulation of cell proliferation and death as well as the ability of transformed cells to invade the host tissue and metastasize. It is increasingly becoming clear that metabolic reprograming plays a critical role in tumorigenesis and metastasis. Therefore, target ing this phenotype is considered as a promising approach for the development of therapeutics and adjuvants. The process of metabolic reprograming is linked to the activation of oncogenes and/or suppression of tumor suppressor genes, which are further regulated by microRNAs (miRNAs) that play important roles in the interplay between oncogenic process and metabolic reprograming. Looking at the advances made in the recent past, it appears that the translation of knowledge from research in the areas of metabolism, miRNA, and therapeutic response will lead to paradigm shift in the management of this disease.
Introduction
Cancer is defined by abnormal and uncontrolled cell division, a phenotype that arises from the alteration of different mec hanisms, leading to misregulation of several protein coding genes. It is nearly 90 years ago that the Nobel laureate Otto Warburg discovered the glycolytic phenotype (aerobic glycolysis) of the cancer cells, where glucose is converted into lactate for energy production rather than performing oxida tive phosphorylation (OXPHOS), even in the presence of oxygen. This is widely known as the Warburg's effect and purportedly supports energy production, macromolecular synthesis, and redox balance essential for tumor growth. 1 This metabolic shift, referred to as the metabolic reprogram ming, is known to be under the influence of both oncogenic activation and downregulation of tumor suppressor genes. 2 Further, as tumors grow, it becomes increasingly difficult for the innermost cells to obtain oxygen from the blood, creat ing a hypoxic environment, which accentuates the metabolic reprograming. 3 The high rate of glycolysis and suppressed gluconeogenesis also help to maintain a low concentration of intracellular glucose, creating a gradient favoring the flux of glucose into the cell, and create micro environmental acidosis compelling evolution of phenotypes with stress resistance and metastatic ability. These alternations enable cancer cells to acquire characteristics different from normal cells: resistance to growth inhibitory factors, proliferation in the absence of exogenous growth factors, evasion of apoptosis, limitless rep lication potential via the reactivation of telomerase, abnormal angiogenesis, and avoidance of destruction by the immune system, invasion, and metastasis. 4, 5 The above essential hall marks of cancer are intertwined with an altered cellintrinsic metabolism, either as a consequence or as a cause. 6 This pro cess of metabolic reprograming is linked to the activation of oncogenes and/or suppression of tumor suppressor genes, which are further regulated by either their activation or inac tivation dynamics, where the microRNAs (miRNAs) appear to play important roles. 7 Furthermore, numerous stud ies revealing the involvement of miRNAs in the regulation of the essential cellular homeostatic pathways suggest that miRNAs can play key roles in tumorigenesis, maintenance, and progression of the neoplastic state. 8, 9 It is increasingly becoming clear that metabolic reprograming plays a critical role in tumorigenesis and metastasis. Given the essential role of miRNAs in tumor development and their global deregula tion, they are ideally suited as either surrogate or therapeutic biomarkers in cancer. 10 11 miRNAs are short, endogenous ∼22 nt RNAs that can play important regulatory roles in a variety of biological pro cesses. 12 They demonstrate complementarity with 3′untrans lated region (3′UTR) of their target messenger RNAs (mRNAs). The miRNAmediated regulation of gene expres sion could be either by posttranscriptional regulation of gene expression leading to target mRNA degradation or repres sion of its translation with consequent decrease in the parti cular protein levels or even by upregulation of the targets. 13 The monocistronic or polycistronic miRNAcoding genes are transcribed by RNA polymerase II into long primary tran script of miRNA (500-3000 bases) containing the hairpin structure, which are converted into precursors of miRNAs (premiRNA, ∼70 bases) by nuclear RNase III Drosha with the aid of cofactor DGCR8. 14, 15 Following nuclear processing, the premiRNAs are exported to the cytoplasm by a nuclear transport receptor, exportin5, and RanGTP before being processed by the cytoplasmic RNase III Dicer into 21nt mature miRNAs duplexes. 16 Finally, the singlestranded miRNA are incorporated into an RNAinduced silencing complex to induce translation suppression or degradation of the target mRNAs depending on the degree of complementa rity with the 3′ UTR of the target mRNA. 17 The miRNAs regulate a plethora of cellular processes through various mechanisms, including direct targeting of the key enzymes or transporters of metabolic products and regulating transcription factors. 18 The first evidence show ing the involvement of miRNAs in cancer came from stud ies on chronic lymphocytic leukemia (CLL), which showed that the critical region most frequently deleted in major ity of the CLL encoded two tumorsuppressive miRNAs -miR15 and miR161. 19 It is now well established that miRNAs play a pivotal role in cancer by regulating onco genes/tumor suppressors and multiple oncogenic signaling pathways, involved in the phenotypic hallmarks of cancer, from the development of autonomous cellular proliferation to acquiring invasive and metastatic capabilities. 20 However, the influence of a few miRNAs appears to be contextual, influencing both progression and suppression of carcino genesis, although interestingly, majority of the tumor sup pressor genes are targets of the miRNAs. 21 As miRNAs are integral nodes in the regulation of important steps of the altered metabolic profile of cancer cells, modulating their activity represents a promising new approach for cancer therapy. The role of miRNA in the general context of can cer including tumor response to various therapies has been extensively reviewed. [22] [23] [24] The role of miRNAs in various human metabolic dis eases such as obesity, diabetes, and cancer has recently gained increasing attention resulting in a paradigm shift in our under standing of the regulation of cancer metabolism. Emerging picture based on miRNA profiling in the preclinical samples and clinical studies shows that miRNAs regulate the meta bolism of normal as well as the transformed cells and plays a critical role in cancer progression/tumor development. 25 Available evidences strongly suggest that miRNAs act directly either by targeting key metabolic transporters and metabolic enzymes or by critical signaling pathways by controlling the expression of oncogenes and/or tumor suppressors.
7 Table 1 provides an overview of the miRNAs involved in the meta bolic reprograming of cancer cells and their functions. While majority of the studies suggest that miRNAs regulate the glucose metabolism during the process of tumorigenesis, fewer studies have also suggested the potential role of altered glucose metabolism in regulating miRNAs contributing to the disease progression. [26] [27] [28] [29] The interplay between oncogenic transformationdriven metabolic reprograming and aberrant miRNAs regulation further establishes their critical role in initiation, promotion, and progression of cancers [30] [31] [32] by creat ing a protumorigenic microenvironment, thus orchestrating processes of evasion of apoptosis, angiogenesis, and invasion/ migration as well as metastases (Fig. 1) . 20 A plethora of evidences indicating the differential expression of miRNAs in normal and tumor samples suggest that miRNAs could serve as use ful tumor profiling tools. The conventional, high throughput oligonucleotide miRNA microarray technique, along with its multiple numbers of variations, makes it possible to profile sub stantial sample numbers with relative ease. 33, 34 It appears that the expression and activation of glucose metabolismlinked miRNAs can act as biomarker signatures together with the metabolic status and may help in the prediction of disease progression and the design of appropriate therapy in the near future. The roles of miRNA in cancer metabolism in relation to proliferation, cell cycle regulation, and cell death and the potential of miRNA related to metabolic reprograming as therapeutic targets have been reviewed earlier. 22, 35 This review focuses mainly on the interplay between miRNA regulation and metabolic reprograming, with an emphasis on their poten tial to influence various hallmark phenotypes associated with carcinogenesis as well as tumorigenesis, such as proliferation, apoptosis, angiogenesis, migration, invasion, and metastasis.
regulation of the Glycolytic Flux by mirNAs
Glycolysis, glutaminolysis, and de novo lipid biosynthesis form a stereotypic platform supporting cancer cell proliferation (Fig. 2) . 36 Cancer cell proliferation can only proceed as meta bolites accumulate to ensure an ample supply of building blocks such as reduced nicotinamide adenine dinucleotide phosphate (NADPH), acetylCoA, and ribose for DNA, RNA, protein, lipid, and complex carbohydrates to prepare for mitosis. 37 The emerging cancer cell rewires its metabolic program to support growth, evade death (through apoptosis), and maintain favor able redox balance. Metabolic reprograming of cancer cells is a complex interplay of regulatory networks involving phospho inositide 3kinase (PI3K), mechanistic target of rapamycin (mTOR), Akt, phosphatase and tensin homolog (PTEN), and adenosine monophosphateactivated protein kinase (AMPK) and can be traced to a "triad" of transcription factors: hypoxia inducible factor1 (HIF1), cMYC, and p53. The underlying mechanisms leading to the Warburg phenomenon/aerobic glycolysis include mitochondrial changes, upregulation of ratelimiting enzymes/proteins involved in glycolysis and intracellular pH regulation, hypoxiainduced switch to anaer obic metabolism, and metabolic reprograming associated with loss of p53 function.
38 Figure 3 provides an overview of the miRNAs involved in the regulation of metabolism achieved by targeting key metabolic enzymes and multiple oncogenic signaling pathways.
The first step in energy metabolism is the entry of glucose into the cells. miRNAs can directly regulate the intracellular glucose levels by modulating gene transcription and expres sion of glucose transporters. Glucose transport (GLUT) receptors are responsible for the transport of glucose by cancer cells along the concentration gradient. miRNA1955p and miRNA143 are known to repress glucose uptake and glycoly sis by inhibiting the expression of GLUT3 and hexokinase 2 (HK2) and AKT signaling pathways, respectively. [39] [40] [41] There fore, repression of these miRNAs would facilitate the entry of glucose into the cancer cells as reported in case of human bladder cancer T24 cells. 39 Glucose metabolism, being the central energy resource of the cell, is quite complex. Following the uptake of glucose through GLUT receptors, a large number of enzymes take part in its catabolism to trioses and pyruvate and ultimately to lactate. miRNA regulation of the glycolytic enzymes further increases this complexity. miR26a inhibits the expression of pyruvate dehydrogenase protein X component (PDHX, a noncatalytic subunit of the PDH complex) by directly target ing the conserved miR26a recognition motif of the 3′ UTR of PDHX mRNA, which efficiently decreases the process of pyruvate-acetylCoA conversion and thus blocks the key ratelimiting step of glycolysis to the citric acid cycle in glu cose metabolism, thus impairing mitochondrial metabolism. 42 Pyruvate kinase regulates the final ratelimiting step of glyco lysis, which catalyzes the transfer of a phosphate group from phosphoenolpyruvate to adenosine diphosphate, yielding one molecule of pyruvate and one molecule of adenosine triphos phate (ATP). 43 Four isoforms of pyruvate kinase (M1, M2, L, and R) exist in mammals and are expressed in different types of cells and tissues. 44 The pyruvate kinase M1 (PKM1) and M2 (PKM2) isoforms result from mutually exclusive alterna tive splicing of the PKM2 premRNA, reflecting the inclusion of either exon 9 (PKM1) or exon 10 (PKM2), respectively. 45 While PKM2 is exclusively expressed in embryonic, prolifer ating, and cancer cells and promotes glycolysis even in an aero bic environment, PKM1 is expressed in normal differentiated tissues and promotes OXPHOS. 46 ,47 PKM (pyruvate kinase isozyme) alternative splicing proteins (PTB1/hnRNAPA1/ hnRNAPA2), which control the inclusion of exon 9 (PKM1) or exon 10 (PKM2), are targeted by miR124, miR137, and miR340. High ratios of PKM1/PKM2 inhibit the glycolysis rate but elevate the glucose flux into OXPHOS. Thus, these miRNAs (miR124, miR137, and miR340) impair cancer growth by counteracting the Warburg's effect by regulating alternative splicing of the PKM gene. 48 The expression of the splicing proteins is also under the tight control of the oncogene, cmyc. 49 Therefore, cMyc could also regulate cancer growth directly through PKM alternative splicing proteins or indi rectly through miR124, miR137, and miR340. In the can cer cells, PKM2 not only supports cell growth via Warburg's effect as a metabolic enzyme but also promotes transactivation of HIF1 target genes as a transcription coactivator.
50 PKM2 is also regulated by miR326, which has tumorsuppressive properties and has been shown to regulate glucose metabolism in glioblastoma cells by targeting PKM2. Functional implica tions of targeting PKM2 by miR326 include reduced growth and enhanced apoptosis, cellular invasion, metabolic activity, ATP and glutathione (GSH) levels, and AMPK in glioma and glioma stem cells. Let-7
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figure 3. mirnas regulate cell metabolism by targeting key metabolic enzymes and multiple oncogenic signaling pathways. mirnas could regulate cell metabolism by modulating the expression of metabolic transporters (like glUT), enzymes of the glycolytic/Tca cycle (HK2, aldolase, PDK1, etc.), key transcription factors involved in oncogenic transformation (p53, c-myc, and HiF-1), or oncogenic signaling pathways (aKT/mTor). Abbreviations: mcT, monocarboxylate transporters; glUT, glucose transporter; PPP, pentose phosphate pathway; lDH, lactate dehydrogenase; gsH, glutathione; naDP, nicotinamide adenine dinucleotide phosphate; HK2, hexokinase 2; PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; lKB1, liver kinase B1; Pgm, phosphoglycerate mutase; oaa, oxaloacetate; sco2, synthesis of cytochrome c oxidase 2; iscU1/2, iron-sulfur cluster assembly proteins; PKm2, pyruvate kinase m2 isoform; PeP, phosphoenolpyruvate; gls, glutaminase; HiF, hypoxia-inducible factor; Pi3K, phosphoinositide 3-kinase; Tigar, TP53-induced glycolysis and apoptosis regulator; PTen, phosphatase and tensin homolog; amPK, adenosine monophosphate-activated protein kinase.
for supporting continuous growth. For example, miR378* expression is regulated by ErbB2 receptor tyrosine kinase 2 and induces a metabolic shift in breast cancer cells by inhib iting the expression of estrogenrelated receptorγ and GA binding protein transcription factor, alpha subunit (60 kDa), two PGC1b partners and important regulators of energy meta bolism. This leads to a reduction in the tricarboxylic acid (TCA) cyclerelated gene expression, such as fumarate hydratase, aconitase, succinate dehydrogenase, and oxygen consumption, decreasing the dependency on OXPHOS for ful filling the energy requirement and increasing the lactate pro duction, thus facilitating cell proliferation. 52 Since PGC1b and PGC1α [transcriptional coactivators of the key gluconeogenic enzyme, glucose6phosphatase, catalytic subunit (G6PC)] play a regulatory role in mitochondrial respiration and biogenesis, miR23amediated suppression of PGC1α could also facilitate a metabolic switch from OXPHOS to anaerobic glycolysis to synthesize anabolic precursors to sustain proliferation of tumor cells. 53, 54 interleukin6 (IL6)/signal transducer and activator of transcription 3 (STAT3) signaling in tumor cells activates the expression of miR23a, which directly targets G6PC and PGC1α, leading to the accumulation of glucose6phosphate (G6P). Therefore, increased G6P levels may aid tumor cells in maintaining high rates of proliferation. 55 On the other hand, overexpression of miR125b results in the repression of many transcripts encoding enzymes implicated in glucose, GSH, and lipid meta bolism including phosphatidylcholine transfer protein, lipase A, lysosomal acid, cholesterol esterase, glutathi one synthetase, acylCoA synthetase shortchain family mem ber 1, HK2, stearoylCoA desaturase 1, AKT2, and pyruvate dehydrogenase kinase 1 (PDK1). 56 Thus, by coordinated fine tuning the expression of a large number of enzymes, miR378*, miR23a, and miR125b act as rheostats to regulate the meta bolic intensity in a given cell for the adaptation of cell metabo lism to a transformed state.
Under hypoxic conditions, miR210 represses ISCU1/2 (the iron-sulfur cluster assembly proteins) and thus decreases the activity of prototypical iron-sulfur proteins controlling mitochondrial metabolism, including complex I and aco nitase. 57 It also represses COX10 (cytochrome c oxidase assem bly protein), another important factor of the mitochondria electron transport chain and the TCA cycle.
58 miR210 is significantly overexpressed in many cancers and represses mitochondrial respiration, thereby indirectly facilitating aero bic glycolysis in cancer. 59 
Metabolic reprograming and Uncontrolled Proliferation: mirNAs as the connecting Link
Cancer cells must integrate multiple biosynthetic demands to drive indefinite proliferation. For this, neoplastic cells are highly dependent on the de novo synthesis of nucleotides to maintain sufficient pools to support DNA replication and the production of RNA for driving protein synthesis. The meta bolic pathways supporting nucleotide production are depen dent on metabolic intermediates provided by glycolysis and the TCA cycle. 60 The nonoxidative part of the pentose phosphate pathway (PPP), controlled by thiamine (vitamin B1) dependent transketolase (TKT) enzyme reactions, allows glucose conver sion to ribose (the 5carbon sugar moiety of nucleotides) for nucleic acid synthesis and oxygenindependent glucose degra dation to lactate, which is of utmost importance for the pro liferation process. 61, 62 Earlier studies in pancreatic cancer cells have shown that pentose cycle contributes to .85% of de novo ribose synthesis in RNA with the majority derived from the nonoxidative (TKTregulated) pathway. 63 The synthesis of purines and pyrimidines is also upregulated in cancer cells, and enzymes that catalyze these pathways, including thymidylate synthase (TS) and inosine synthetase 2, are subject to Myc induced upregulation. Myc stimulates these genes involved in nucleotide metabolism and specifically interacts with the E2F family of transcription factors to drive proliferating cells into S phase for DNA replication. [64] [65] [66] miR1, which is a tumorsuppressive miRNA, has been found to be silenced by promoter methylation in primary human hepatocellular carcinoma (HCC). 67 It directly targets glucose flux through the PPP by inhibiting multiple enzymes within the PPP: glucose6phosphate dehydrogenase (G6PD), 6phosphogluconate dehydrogenase (6PGD), and TKT. The shift in the primary glucose metabolism caused by reduced lev els of miR1 facilitates glycolysis, nucleotide synthesis through the production of ribose5phosphate, and regeneration of NADPH to counter oxidative stress through PPP, promoting tumor cell proliferation and inhibition of apoptosis. 68 Of the numerous Akt target proteins reported to date, mTOR appears to be the most critical downstream effector of Aktdependent cell proliferation and altered susceptibility to oncogenic transformation. 69 mTOR critically governs the cell ular growth and metabolic processes of all eukaryotic cells by precisely integrating the extracellular stimuli with amino acid availability and intracellular energy. 70 The activation of mTOR signaling leads to an increase in the protein synthesis of HIF1α in response to growth factors and PI3K/Akt signaling, and thus, leads to enhanced expression of glycolytic enzymes, including lactate dehydrogenase isoform B (LDHB), PKM2 and glucose transporter 1 (GLUT1). 71, 72 While miR126 impedes tumor cell growth by targeting the p85b subunit of PI3K, the trans lational repression of mTOR1 and cmet by miR199a3p has been reported in HCC. 73, 74 As PI3K/Akt triggers downstream signals to mTOR for cellular growth and proliferation, the loss of miR126 and miR199a3p could facilitate tumor growth.
Recently, the overexpression of miR155 has been found to increase the rate of glucose consumption and lactate pro duction through the regulation of numerous enzymes involved in glucose transport and anaerobic glycolysis, including HK2, GLUT1, phosphofructokinase 2, pyruvate dehydrogenase, PKM2, and lactate dehydrogenase isoform A (LDHA). miR 155 upregulates HK2 through the activation of STAT3 and suppression of miR143, which can directly target HK2, lead ing to increased rates of glucose consumption through aerobic glycolysis and lactate production that are required to support the high rate of proliferation. 75 More recently, a novel role of miR155 in cancer metabolism through the upregulation of thiamine has been reported in breast cancer cells. Thiamine (vitamin B1) is a crucial cofactor of various metabolic enzymes such as pyruvate dehydrogenase, alpha ketoglutarate dehydro genase, and TKT. Bioinformatics and metabolomic approaches have clearly established a positive correlation between miR155 and thiamine level. miR155 appears to be involved in thiamine homeostasis by regulating the expression of two thiamine transporter genes (SLC19A2, SLC25A19) and thia mine pyrophosphokinase1 at both the RNA and protein level, thus implicating the role of this oncogenic miRNA in cancer cell metabolism, leading to higher rates of proliferation.
role of mirNAs in the suppression of Apoptosis
Cancer cells show an increased resistance to the intrinsic apop totic pathway through the inhibition of the release of cyto chrome c from mitochondria by a mechanism dependent on glucose metabolism, which allows for their longterm survival. 77 The proapoptotic activity of cytochrome c is influenced by its redox state, and the increase in reactive oxygen species (ROS) following an apoptotic insult leads to the oxidation and activa tion of cytochrome c. However, in cancer cells, cytochrome c is reduced and held inactive by intracellular GSH, whose levels are maintained in cells by NADPH, generated as a result of glucose metabolism by PPP. In addition, the enhanced level and mitochondrial association of HK2 also impair the release of cytochrome c from mitochondria. 78 Thus, the reduced levels of miR1 could also offer an adaptive advantage for cancer cell evasion of apoptosis and for longterm survival through dere pression of the PPP and inactivation of cytochrome c.
Oncomir1 or the miR1792 polycistron is a direct tran scriptional target of myc protein, which consists of a cluster of six mature miRNAs -miR17, miR18a, miR19a, miR20a, miR19b1, and miR92a1. 79 The tumor suppressors, p21 and PTEN, and the proapoptotic protein Bim have emerged as important targets repressed by oncomir1derived miRNAs. 80 The miR1792 cluster modulates the tumor growth by inhib iting HIF1α expression and E2F1, thereby influencing apop tosismediated cell death through the antioxidant response element (ARE) p53 pathway. 81, 82 Thus, miRNAs within the mir1792 cluster appear to function cooperatively as onco genes, possibly by targeting cell cycleregulating proteins and apoptotic factors that are activated in response to the overex pression of MYC, leading to continuous proliferation.
PI3K/Akt signaling activation leads to the transloca tion of HK2 to the mitochondrial membrane, facilitating its binding to the voltagedependent anion channel, negatively modulating truncated BH3interacting domain death ago nist, and BCL2 antagonist of cell death to inhibit apoptosis. 83 Cells lacking the proapoptotic Bcl2 family proteins, Bax and Bak, resist cell death for prolonged periods under conditions of nutrient starvation through the activation of autophagy and use of alternate fuels. 84 The BCL2 expression is inhibited at the posttranscriptional level by miR15 and miR161, sug gesting that the somatic deletion of miR15 and miR161 aids in the development of leukemias, lymphomas, and carci nomas by allowing tumors to sidestep apoptosis, pointing to their tumorsuppressive role. 85 Similarly, miR122, a hepato specific miRNA, is frequently downregulated in human HCC. 86 The decreased miR122 expression helps the cells to evade cell death, a cardinal feature of cancer cells, by upregu lating Bclw and increasing the Bclw/Bax ratio. 87 miR125b is upregulated and stimulates androgenindependent growth in prostate cancer by targeting Bak1 (a member of the proapop totic Bcl1 family of proteins), thereby acting as an oncogene in the neoplastic progression of prostate epithelium. 88 It appears that the stimulation of the PI3K/Akt pathway by miRNAs underlies the evasion of cell death in cancer cells. miR21 has been found to be overexpressed in a wide variety of human cancers 30, 89, 90 and is known to stimulate prolifera tion, migration, and invasion by targeting the PTEN tumor suppressor gene, leading to the activation of PI3K/Akt path way. It also suppresses the activation of caspases and caspase activated DNase, leading to decreased apoptotic cell death, which suggests that aberrantly expressed miR21 may con tribute to the malignant phenotype by blocking the expression of critical apoptosisrelated genes. 91, 92 The miR1792 cluster is markedly increased in lung can cer, especially in the most aggressive form, smallcell lung cancer, and is implicated in enhancing lung cancer cell growth by targeting two tumor suppressor genes, PTEN and RB2. 93, 94 miR19, a component of miR1792 cluster, activates the Akt/ mTOR pathway, thereby functionally antagonizing PTEN to promote cell survival and metabolism. Further, PI3K/Akt signaling is known to strongly promote glucose metabolism and fatty acid synthesis by upregulating GLUT and glycolytic enzyme activity. 95 
Facilitation of tumor Angiogenesis and Metastasis by mirNAs
During the course of cancer progression, there occurs an imbalance between angiogenic and proangiogenic factors resulting in an inclination toward proangiogenic stimuli for the growth of the tumor bulk and its metastatic spread. The altered angiogenic phenotype is mirrored by aberrant miRNA profile mediated by the metabolic reprograming. The involve ment of miRNAs in the modulation of the angiogenic response to metabolic alterations associated with oncogenic process is discussed further in detail.
Deregulated expression of certain miRNAs, such as Let7, miR27, and miR143, has been associated with the metabolic status in pathological conditions such as obesity and diabetes. 96, 97 Interestingly, these miRNAs have also been found to be aberrantly expressed in the process of carcino genesis, indicating a plausible link between obesity, diabetes, inflammation, and cancer. 98 Studies using calorie restriction and dietinduced obesity in colon carcinogenesis have shown that these differential diets altered several biological pathways previously hypothesized to be involved in obesity and can cer, including inflammation, insulin growth factor (IGF)1, adipokines, and miRNAs. 99 Certain miRNAs are known to depend on glucose dynamics for their function. For example, miR451 in gliomas has been shown to adapt its expression and function differentially depending on the glucose avail ability allowing survival adaptation to locoregional metabolic stress by activating the liver kinase B1 (LKB1)/AMPK sig naling pathway. Under sufficient glucose conditions, increased expression of miR451 promotes cell growth, while it reduces proliferation and enhances migration and survival during low levels of glucose. [100] [101] [102] As the cancer progresses, Let7 is downregulated leading to an increased expression and activity of metabolismrelated factors, such as Ras, cmyc, and Lin28, in cancer cells. 103, 104 In breast cancer, let7 inhibits Lin28 mediated insulin/PI3K/mTOR signaling cascade, inhibit ing cancer progression. 105 Initially, it was discovered that the oncomir, miR378*, is linked to the metabolic switch in breast cancer cells, thereby shutting down the OXPHOS/TCA cycle and upregulating the glycolytic pathway further facilitating the cancer progression. 52 Later, miR378* was also classified as proangiomir and shown to enhance angiogenesis via regu lating the two transcription factors, SuFu and Fus1, 106 thus, accentuating the growth, proliferation, and progression of cancer by dysregulating energy metabolism.
The oncogenic miRNA, miR21, is known to induce tumorassociated neovascularization by directly targeting PTEN and activating PI3K/Akt as well as ERK1/2 signal ing pathways, which increases HIF1α and vascular endothe lial growth factor (VEGF) expression. 91, 107 In patients with diabetesassociated vascular disease, increased miR21 levels/ expression has been found in response to high systemic glu cose, protecting endothelial cells (ECs) against high glucose induced apoptosis. 108 Interestingly, miR221/222 gene cluster, which is an activator of PI3K/Akt, has been found to inhibit the process of angiogenesis. 109, 110 This cluster plays an impor tant role in maintaining the EC differentiation and integrity in quiescent form. However, it inhibits proangiogenic activ ity, proliferation, and migration of ECs possibly by repressing ETS1 signaling upon forming a complex of protooncogene ETS1 and miR222 (ETS1/miR222). 111, 112 Similarly, miR126 is also known to maintain vascular integrity and reported to inhibit tumor angiogenesis through the regula tion of VEGFA signaling. 113 Both glucose levels and hypoxia in the tumor microenvironment are reported to downregulate miR126. Suppression of miR126 upregulates the proangio genic factors and causes invasive growth in cervical cancer. 114 The proangiogenic activation by suppression of miR126 has also been associated with an increase in mitogenactivated protein kinase (MAPK) and PI3K signaling in response to proangiogenic factors. 115, 116 miR18a and miR19a/b, from miR1792 cluster, have been shown to regulate proangiogenic effect under the influence of activated MYC through thrombospondin1 targeting and hence tumor growth as shown in murine colon carcinoma. 117 MYC is also known to induce another very important onco genic miRNA, miR9, that is outside the miR1792 cluster and has been implicated in tumor cell invasiveness and metas tasis. 118, 119 In a breast cancer xenograft model, miR9 has been shown to promote tumorigenesis by enhanced tumor cell invasion and metastasis. This has been attributed to the downregulation of Ecadherin, thereby inducing βcatenin activation leading to increased VEGF levels. 118, 119 miR155 is a prominent oncomir that plays an impor tant role in the metabolically driven oncogenic process in cancers of the breast, lung, stomach, and lymphatic system. 120 miR155 expression in cancer cells regulates the multiple aspects of tumorigenesis, including transforming growth factor mediated epithelial-mesenchymal transition (EMT), along with the migration and invasion by Ras homolog gene family, member A. 120 As discussed earlier, miR155 in breast cancer cells is reported to induce aerobic glycolysis via HK2 upregulation through irreversible repression of mir143, which is a negative regulator of HK2. 75 Most recently, rosmarinic acid has been shown to possess antiWarburg's effect induced by the downregulation of miR155 and inhibition of inflam matory IL6/STAT3 pathway, thus inhibiting the gastric can cer (in vitro and in vivo) and suggesting an important link between the Warburg's effect, inflammation, and tumorigen esis 121 Besides cancer cells, the overexpression of miR155 observed in the activated macrophages and recruited proan giogenic neutrophils suggests its involvement in the protum origenic and proangiogenic state early during the carcinogenic process. 122, 123 Cytokines released during the inflammation has been shown to upregulate the glycolysis by miR155/miR143 cascade in breast cancer cells. 124 Inflammationinduced increase in miR155 levels represses miR143, which is a nega tive regulator of HK2, by targeting its transcriptional activa tor CCAAT/enhancer binding protein beta (C/EBPβ)and also enhances the transcription of HK2 by targeting suppressor of cytokine signaling 1 (SOCS1), a repressor of Janus kinase/ STAT signaling, thereby activating protumorigenic inflam matory STAT3. 75, 124 Thus, the miR155SOCS1STAT3 HK2 and miR155C/EBPβmiR143HK2 cascades display a direct link between miRNA regulation of inflammation mediated upregulated glycolysis and cancer. Recent observa tions on a differential effect of miRNA deregulation on the growth of normal and tumor cells 35 suggest that miRNAs may be better targets for developing anticancer therapeutics. 125 However, similarities in the programming of metabolism in cancer cells and the activated immune cells 126 may pose not only problems of differential response but also efficacy at the systemic level as immune modulation contributes to the local tumor control. 127, 128 During cancer progression, the limitation of nutrients in the micro milieu of the tumor gives rise to the upregulation of glucose metabolism for catering the energy requirements related to the tumor cell survival and metastasis to other sites involving processes such as invasion, migration, and EMT. 129 Emerging evidences suggest that miRNAs can also act at distant sites upon transport through the bloodstream in the form of mature or premiRNA packaged into vesicles (exo somes), thereby regulating the expression or activity of target protein. miRNA, miR122, has been recently shown to repro gram the glucose metabolism by inhibiting pyruvate kinase in non tumor cells of the distant premetastatic environment. 129 This host-tumor crosstalk causes increased glucose availability to the tumor cells in the premetastatic niche, favoring meta stasis in patients with breast cancer. 130 In addition to tumor cells, the activated tumorassociated stromal cells and ECs are known to rely on glycolysis during disease progression. 131 The suppression of glucose metabolism in tumor stroma by secreted miR122 is a sustenance mechanism during local nutrient limitation and dissemination to a secondary site for its establishment and further growth.
It has been recently reported that miR7 plays a tumor suppressor role by downregulating the metabolic IGF1R/ Akt and PI3K/Akt/mTOR signaling pathway, and its over expression reverses the invasion, extrahepatic migration, and metastasis of HCC as a consequence of suppressed glu cose metabolism. 132, 133 Similarly, the downregulation of miR1291 has been shown to enhance proliferation, mig ration, and invasion of renal carcinoma cells through targeting of SLC2A1/GLUT1. 134 There exists an inverse relationship between miR1291 and GLUT1, where the upregulation of SLC2A1 ⁄GLUT1 facilitating the GLUT is associated with poor prognosis in a variety of cancers, 135, 136 while a positive correlation of lymph node metastasis with enhanced SLC2A1/GLUT has been shown in head and neck carcino mas. 137 Nuclear factor erythroid2related factor 2 (leucine zipper family transcription factor) has been shown to promote neoplasia via epigenetic regulation of miR1 and miR206, 138 which leads to metabolic reprograming through the activa tion of the PPP. This altered metabolism is accompanied by miR1 tumor suppressor activity, which is corroborated by the miR1mediated alteration in the cellular organization of Factin, thus inhibiting the invasion and filipodia forma tion by tumor cells. 139 These studies provide a direct evidence of functional outcome of miRNA regulation mediated by oncogenic-metabolic interplay.
Besides targeting the major ratelimiting steps in glycolysis, miRNAs are also involved in the regulation of some important intermediate steps of glycolysis, affecting tumor angiogenesis and metastases. For example, Aldo A, which catalyzes fruc tose 1,6bisphosphate into glyceraldehyde 3phosphate and dihydroxyacetone phosphate, is suppressed by miR15a/161 cluster. 85 Similarly, phosphoglucose isomerase, which plays an important role in invasion as well as metastasis, has been shown to be under the control of miR200 family (miR200a, miR200b, and miR200c). [140] [141] [142] The miR200 family inhibits metastatic potential and angiogenesis by maintaining epithelial characteristics, thereby impairing EMT and targeting IL8 and chemokine (CXC motif) ligand 1 (CXCL1) secreted by tumor and the associated endothelium. 141, 143 As discussed ear lier, miR1792 oncomir cluster regulates either positively or negatively numerous pathways/processes, resulting in increased invasion, metastasis, and angiogenesis involving the induc tion of PI3K/AktmTOR pathway associated with abnormal glucose metabolism. 95, 144 Altered miRNA expression profiles have been observed in hypoxic conditions of tumor microenvironment. Increased HIF levels results in the modulation of glucose uptake, glu cose metabolism, and OXPHOS, thereby promoting inva sion, metastasis, and angiogenesis. [144] [145] [146] An increased level of HIFdependent hypoxamir, miR210, has been found to participate in the upregulation of glycolysis by inhibit ing mitochondrial respiration (OXPHOS). miR210, also known as proangiomir, induces the expression of glucose transporter, Glut1, followed by the upregulation of VEGF and plateletderived growth factor, creating a proangiogenic micro environment. 147 The angiogenic regulation by hypoxia is an important component of adaptive mechanisms, which bridges the metabolic demand with the vascular network oxygen supply. Recruitment of bone marrowderived vas cular modulatory cells to regulate tumor angiogenesis has been shown to be under the regulation of HIF1α. 148 The overex pression of miR210 in ECs (in-vitro) stimulates angiogenesis with increased migration potential and its downregulation reduced hypoxiainduced capillary formation. 149 Receptor tyrosine kinase, EphrinA3, that is associated with vas cular remodeling is identified as another important miR210 target. 150 Interactions between miRNAs and HIF add another molecularlevel complexity in hypoxiadrivenaltered glucose metabolism supporting invasion, angiogenesis, and metastasis in various tumor types such as lung, breast, and gliomas.
Several studies have established an association between p53 mutations and the star hallmark of cancer, that is, meta bolic reprograming (Warburg's effect) in a majority of cancer types. 151 Recently, miR34a, a direct transcriptional target of p53, has been shown to function as a tumor suppressor inhibit ing metastasis and angiogenesis indirectly by repress ing glycolysis via the inhibition of glycolytic enzymes such as HK1, HK2, glucose6phosphate isomerase (G6PI), and PDK1 and also by directly targeting CD44 in bladder can cer. 152 Various isoforms of CD44 gene have been attributed to EMT, angiogenesis, invasion, metastasis, invasion, migration, and metabolism correlated with increased Akt activity. [153] [154] [155] Further, overexpression of miR34a was shown to downregu late matrix metalloproteinase (MMP)1 and MMP9 expres sion, strongly inhibiting migration and invasion as shown in colon cancer cells, 156 while p53 mutation or loss of miR34a function has been shown to facilitate invasive and migratory phenotype through upregulated glycolysis.
A symbiotic relationship between cancer cells and cancerassociated fibrobalsts as well as ECs involving peroxide generated by tumor cells and lactate by stromal cells has been recently shown to facilitate tumor growth and meta stasis. 157, 158 It appears that miRNAs facilitate the bidirec tional communication between cancer cells and the stroma through microvesicles, thereby promoting angiogenesis and tumor growth (Fig. 4) . Tumor suppressor miRNA, miR320, influences glycolysis via downregulation of the PI3K/Akt pathway.
159 miR320 is a crucial player of the tumorsuppres sive PTENcontrolled axis in stromal fibroblasts and is con sidered as metabolic stress/status responsive miRNA. 160 The attainment of the protumorigenic microenvironment with increased migration, invasion, and neovascularization upon loss of PTEN and miR320 is shown to be linked with unique tumorpromoting secretory factors called secretomes. 160, 161 In vitro studies in human umbilical vein endothelial cells have shown a significant decrease in the expression of miR320 under high glucose conditions (similar to diabetes), while upregulating the expression of ET1, VEGF, and FN through its direct influence on ERK1/2 MAPK. 162 Similarly, sup pression of miR320a has been found to enhance the levels of PFKm (muscle type), the ratelimiting enzyme of glycolysis, in the lung adenocarcinoma tissue and muscle, suggesting a distinct link between miR320mediated glucose regulation and malignant phenotype. 163, 164 Further, miR26a is also a direct regulator of PTEN, as seen in human as well as in rodent model gliomas and lung where PTEN loss has been associated with deregulated Akt activity and miR26a expres sion with metastatic and angiogenic potential. [165] [166] [167] 
role of mirNAs in the regulation of oncogenic signaling Pathways closely Linked to Metabolic reprograming
The process of carcinogenesis is marked by progressive changes in intra and intercellular signaling pathways that are closely associated with oncogenic transformation and/or metabolic reprograming. Significant advances that have been made in unraveling the role of miRNAs involved in the alterations of certain key signaling pathways will be discussed here.
PI3K/Akt/mtor pathway. The serine/threonine kinase Akt -also known as protein kinase B -is the most frequently activated protein kinases in human cancers. The predomi nant mechanisms by which Akt is activated in human cancer are through mutational inactivation of PTEN by NADPH through a redox modification mechanism and mutational activation of the catalytic subunit of PI3K. 168, 169 Akt hyper activation is closely associated with cellular processes that contribute to the classical Warburg's effect in cancer cells and can contribute in the process of carcinogenesis by inhibiting apoptosis, increasing cell proliferation, and/or by accelerating oncogenic mutation rates. 170 The expression of miR181a is found to be enhanced in colon cancer cells, which induce a metabolic shift by inhibit ing the expression of PTEN, leading to an increase in phos phorylated Akt. The increase in lactate production induced by miR181a as a result of upregulated glycolysis in response to activated PI3K/Akt signaling supports the rapid growth of cancer cells and suppresses apoptosis. Cyclin D1, a cell cycle checkpoint protein, is also upregulated in miR181a overexpressing cells, further supporting the regulation of cell growth by miR181a.
171
AMPK signaling. In untransformed cells, the 5′AMPK pathway is the major cellular sensor of energy availability. AMPK is activated by metabolic stress to promote energy con servation and glucose uptake, allowing cells to survive periods of low energy (ATP) availability.
172 LKB1 (also known as ser ine/threonine kinase 11), a known tumor suppressor, is the key upstream activator of AMPK.
173 miR451 regulates AMPK signaling in response to glucose levels in glioma cells by target ing the binding partner of LKB1, CAB39 (MO25a), thereby regulating cell survival, motility, and proliferation. Under con ditions of sufficient nutrients (glucose), elevated miR451 lev els reduce the activation of LKB1/AMPK pathway, facilitating cell proliferation by allowing unrestrained mTOR activity and inhibition of apoptosis, promoting survival and motility in response to metabolic stress in glioma cells. 100 Accordingly, decreased miR451 levels correlate with poor prognosis in gas tric and colorectal cancers, perhaps by reduced ability to tar get macrophage migration inhibitory factor, which is a known activator of AMPK signaling. 174, 175 Thus, the major function of miR451 appears to be the suppression of AMPK. miR33a and miR33b have also been shown to control the expression of AMPactivated kinase 1 (Ampkα1) and sir tuin 6 (Sirt6), which are involved in the regulation of lipid and glucose metabolism. Inhibition of AMPKα1 by miR33 may increase the activity of the key regulated lipogenic enzymes 3hydroxy3methylglutarylCoA reductase and acetylCoA carboxylase to boost the intracellular levels of cholesterol and fatty acids to sustain proliferation of tumor cells. In addition, insulin receptor substrate 2 (Irs2), an adaptor protein that con trols insulin signaling in the liver, has also been shown to be a miR33 target, thereby affecting the signaling of a complex downstream network of proteins, including Akt phosphoryla tion and forkhead box O1 cytoplasmic localization.
176
regulation of HIF signaling. The responses of tumor cells to hypoxia are at least partially orchestrated by activa tion of the HIFs. HIF1, a transcription factor composed of HIF1α and HIF1β subunits, is stabilized and activated in response to low oxygen tension and plays critical roles in the adaptation of tumor cells to a hypoxic microenvironment. 177 It activates the transcription of genes, such as GLUT1 (glucose uptake) and LDHA (lactate production), that are involved in crucial aspects of cancer biology, including glucose meta bolism, cell survival, angiogenesis, and invasion and decreases reliance on mitochondrial OXPHOS.
178
HIF1α induces cell cycle arrest by activating p21 or p27 and apoptosis through stabilization of p53. 179 Induction of miR1792 through transcriptional activation by cmyc downregulates HIF1α, leading to evasion of apoptosis and unrestrained growth. 144 HIF1α level is also regulated by miR199a, which directly targets HIF1α 145 and several other miRNAs, whose levels are altered in multiple cancers, namely, miR20a, miR20b, miR21, miR101, miR106a, miR106b, miR150, and miR200b, which are predicated to target Von Hippel-Lindau factor, an E3 ubiquitin ligase that marks HIF1α for degradation under normoxic conditions. 180 miR424, a hypoxia inducible miRNA, targets cullin 1 (CUL2), a scaffolding protein critical to the assembly of the ubiquitin ligase system, and hence, stabilizes HIF1α. 181 miR22 and miR20b also act as tumor suppressors by inhib iting hypoxia signaling and suppressing HIF1α translation. Since cmyc has been shown to limit miR22 expression, tumors overexpressing cmyc might be expected to have lower levels of miR22, higher levels of HIF1α, and VEGF. There fore, miR22 may also play a significant role in the regulation of tumor angiogenesis and cell survival.
182
regulation of c-myc. The MYC oncogene is a key trans forming oncogenic agent and frequently dysregulated in a wide variety of human tumors. 183 In normal cells, myc protein levels are transiently elevated during cell growth but decline to low levels as cells exit the cell cycle. 184 Dysregulated MYC induces immortalization, genomic instability, independence of growth factors, and escape from immune surveillance lead ing to a cancerous state. 185 With E2F1, cMyc induces genes involved in nucleotide metabolism and DNA replication, and miRNAs that homeostatically attenuate E2F1 expression for safe passage of cells through S phase, whereas in association with HIF1α, it programs the adaptive response of cells to hypoxic conditions. 65, 186 MYC directly regulates the expres sion of genes that encode the enzymes in the nucleotide biosynthetic pathways and in the feeder pathways for the production of the precursors of all nucleotides including the amino acids aspartate, glutamine, serine, glycine, and CO 2 , as well as coordinates RNA and protein biosynthesis. [187] [188] [189] It has been shown that the inhibition of CMYC results in the repression of several enzymes ratelimiting for nucleotide metabolism including TS, inosine monophosphate dehydro genase 2, and phosphoribosyl pyrophosphate synthetase 2 (PRPS2). It also leads to the depletion of intracellular deoxy ribonucleoside triphosphates, and subsequently, suppression of proliferation. 64 PRPS2 couples protein and nucleotide bio synthesis through a specialized cisregulatory element within the PRPS2 5′ UTR, called the pyrimidinerich translational element (PRTE), which is controlled by the oncogene and translation initiation factor eIF4E downstream of Myc acti vation. Thus, PRTE enables translational regulation by Myc to directly increase nucleotide biosynthesis proportionately to the increased protein synthesis rates of cancer cells. 190 In addition to glycolysis, cmyc stimulates glutamine catabo lism to fuel growth and proliferation of cancer cells. 82 Glutamine serves as a nitrogen source for multiple steps of both purine and pyrimidine synthesis. Also, glutaminolysis is the major mecha nism for TCA anapleurosis to replenish TCA intermediates diverted for nucleotide synthesis.
191 miR23 targets glutami nase (GLS) mRNA and inhibits the expression of GLS protein, inducing mitochondrial dysfunction leading to cell death. cmyc transcriptionally represses miR23a and miR23b, which target GLS mRNA, resulting in a greater expression of GLS pro tein. 192 Tumor cells grown in glutamine have been shown to have increased nuclear factorkappa B p65 subunit translocation to the nucleus where it controls glutamine metabolism by down regulating miR23a levels by binding to its promoter. 193 There fore, p65 activation decreases miR23a expression, facilitating glutamine consumption and faster proliferation, allowing cancer cells to use this alternative source of carbon and favoring their adaptation to the altered metabolic environment.
After conversion of glutamine to glutamate, glutamate can also be converted to proline through ∆1pyrroline5 carboxylate (P5C) and vice versa. Proline oxidase, also known as proline dehydrogenase (POX/PRODH), the first enzyme in proline catabolism, is directly induced by p53 and is a mitochondrial tumor suppressor that inhibits proliferation by causing cell cycle arrest at the G2M checkpoint and inducing apoptosis.
194 myc regulates proline metabolism by suppressing POX/PRODH expression primarily by upregulating miR23b* and increasing the enzymes of proline biosynthesis from glutamine, includ ing P5C synthase and P5C reductase 1. Suppression of myc leads to an increase in POX/PRODH ratio inducing ROS generation and apoptosis, leading to decreased cell prolifera tion and growth. 195 Besides miR23a, IL6/STAT3 signaling also upregulates the expression of cmyc, which in turn can repress miR23a expression. 196 Thus, mycinduced suppression of POX/PRODH contributes to mycmediated changes in cell behavior including proliferation and metabolic reprograming that, in turn, contributes further in tumor progression.
Cmyc also supports the tumor growth by cmyc mediated transactivation of the RNAbinding proteins Lin 28a/b, which repress the let7 miRNA family members. 197 The let7 miRNA family members act as tumor suppres sors by negatively regulating the translation of oncogenes (VKiras2 Kirsten rat sarcoma (KRAS), Neuroblastoma rat sarcoma (NRAS), VMyc Avian Myelocytomatosis (MYC), and Highmobility group AThook 2 (HMGA2) and cell cycle regulators and are either suppressed or deleted in various human cancers. 198 For example, let7 has been shown to func tion as a tumor suppressor in lung cells, directly controlling cellular proliferation by negatively regulating the human RAS genes, as well as a few key cell cycle protooncogenes, such as CDC25a, CDK6, and cyclin D, thus reducing flux through the pathways promoting G1 to S transition. 199, 200 The RNAbinding proteins, Lin28a and Lin28b (col lectively referred to as Lin28a/b), are highly expressed during normal embryogenesis and upregulated in some cancers to potently and selectively block the maturation of let7. 201, 202 By repressing the biogenesis of let7 miRNAs and in some cases through direct mRNA binding and enhanced transla tion, Lin28a/b regulates an array of targets involved in cell prolife ration and differentiation. 203 Interestingly, the let7/Lin 28 axis regulates glucose metabolism as well in cancer cells. Overexpression of let7 or loss of Lin28a results in insulin resistance and impaired glucose tolerance that occurs, in part, through the let7mediated repression of multiple components of the insulin/PI3K/mTOR pathway, including IGF1R, INSR, and IRS2.
105 PI3K/Akt signaling is known to promote GLUT4 translocation to upregulate glucose uptake, while mTOR sig naling can promote glucose uptake and glycolysis by modulat ing gene expression independently of GLUT4 translocation. 204 The altered metabolism of anaerobic glycolysis confers sev eral advantages to cancer cells such as adequate energy supply, biosynthesis of required molecules, invasiveness due to high lac tate production, and also protection against the apoptotic stimuli. The lactate generated in the cytosol is secreted outside the cells by the monocarboxylate transporters, whose membrane levels are regulated by CD147, a broadly expressed plasma membrane glycoprotein. Since the expression of CD147 is also regulated by let7b, repression of glucose metabolism by let7 in cancer cells is compensated by the upregulation of Lin28a/b, which promotes tumor growth, migration, and tumor metastasis.
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p53 signaling. The role of p53 as a central component of the stress response machinery is well established. Since any stress signal, whether extrinsic or intrinsic to the cell, can activate p53, the responses to metabolic stress resulting from limited nutrient, energy, or O 2 availability in cancer cells also involve p53. p53 inhibits glycolysis by transcriptionally repressing GLUT1 and GLUT4 and enhances mitochondrial respiration by inducing synthesis of cytochrome c oxidase 2 (SCO2) and glutaminase 2 (GLS2). In tumors where p53 is highly mutated and SCO2 is low, glycolysis appears to be the safest option to meet the highenergy demand of prolife rating cells. p53 enhances the expression of TP53induced gly colysis and apoptosis regulator, while inhibiting the expres sion of phosphoglycerate mutase, resulting in the inhibition of glycolysis.
206 p53 regulates and itself is regulated by vari ous miRNAs. It activates the transcription of miR34a and miR194/miR215 cluster, which functions as effectors in the p53 signaling pathway by inducing cell cycle arrest and apop tosis.
207 miR34a indirectly activates p53 by downregulating SIRT1, which negatively regulates p53 through deacetyla tion, leading to induction of p21 and PUMA and ultimately apoptosis. 208 As SIRT1 activity is NAD dependent, the metabolic state of the cell may also influence the effective ness of this regulation. miR34a also inhibits cellular gly colysis by directly targeting hexokinase 1 (HK1), HK2, and G6PI. Loss of miR34 through genetic or epigenetic mecha nisms interrupts this feedback resulting in lower p53 activity and thereby provides a selective advantage for cancer cells by increasing glycolysis.
151 p53 also suppresses the transcription of some tumorigenic miRNAs such as miR1792 family. 209 Activation of miRNAs, miR161, miR143, and miR145, by p53 through enhanced posttranscriptional processing fur ther controls the cellular division through cell cycle arrest by TranslaTional oncogenomics 2015:7 targeting KRAS and CDK6. 210 miR25, miR30d, miR504, and miR125b directly target p53 3′UTR and hence impair p53 response and promote tumorigenicity through direct reduction in p53 protein levels. 211 miR372 and miR373 are two other oncogenic miRNAs that promote cell proliferation and tumor development by neutralizing p53mediated CDK inhibition, possibly through direct inhibition of expression of the tumor suppressor gene LATS2 (large tumor suppres sor kinase 2). 212 Since p53 is mutated/negatively regulated by miRNAs in most of the cancers, the tumorsuppressive func tion of p53 of inhibiting glycolysis is compromised to support the high rates of proliferation of cancer cells.
summary and conclusions
Although metabolic reprograming in the form of Warburg phenotype, regarded as one of the most important hallmarks of cancer, is known for nearly a century, translation of this knowl edge into the development of therapeutics unfortunately has been not encouraging so far. While the initial excitement of using the glycolytic inhibitor 2DG as a therapeutic 213 was soon aborted due to undesirable toxicity in the form of diaphoresis and disturbances in the central nervous system, the 214 deploy ment of this analog as an adjuvant in the radio and chemother apy has only made a modest progress despite excellent tolerance and minimal toxicity. 11, [215] [216] [217] [218] [219] [220] With increasing knowledge about the miRNAmediated regulation of the interplay between the metabolic reprograming and the malignant phenotype, includ ing resistance to therapies, hopefully, we will identify critical miRNA targets or events regulated by them that will pave way for the development of novel therapeutics with hightarget specificity and minimum nontarget (normal tissue/cells) effects. Looking at the rate of advances made and the nature of insights obtained in the last couple of years, it appears that the transla tion of knowledge from research in the areas of metabolism, miRNA, and therapeutic response is round the corner.
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